BlackRock Fund Advisors has recently announced that it has increased stake in Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) by 3.78%. After grabbing 11.54 million shares, the institutional investor is now in possession of 0.42 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.66% having worth around $372.87 million. Moreover, The Vanguard Group, Inc. increased its share by 0.14 million to have a control over 10.01 million shares. And SSgA Funds Management, Inc. raised its holdings to 0.72 million shares by acquiring 5.97 million shares or 5.51% of the stake.
Arrowhead Pharmaceuticals Inc. (ARWR) concluded trading on 03/16/23 at a closing price of $24.44, with 2.23 million shares of worth about $54.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.71% during that period and on Thursday the price saw a loss of about -3.48%. Currently the company’s common shares owned by public are about 106.04M shares, out of which, 103.30M shares are available for trading.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 12 analysts are covering the ARWR stock and their offered price forecasts bring an average price target of $63.62. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $90.00 and could fall to a lowest price of $21.00. The stock’s current price level is 59.63% above of average price target set by the analysts, while a rise to estimated low would result in loss of -16.38% for the stock. However, touching the estimated high of $90.00 would mean a gain of 72.84% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 45 times over the past 12 months. They bought 587,470 shares in 16 of the transactions. In 29 selling transactions, insiders dumped 800,227 shares.
iShares Core S&P Mid Cap ETF, Vanguard Total Stock Market Index, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Arrowhead Pharmaceuticals Inc. iShares Core S&P Mid Cap ETF is currently holding 3.3 million shares of worth totaling $106.59 million. The company recently came buying 7476.0 shares which brought its stake up to 3.05% of the company’s outstanding shares. Vanguard Total Stock Market Index bought 35604.0 shares, after which its hold over company’s outstanding shares expand to 2.85%, leaving 3.09 million shares with the mutual fund that have a worth of about $99.86 million. Vanguard Small Cap Index Fund, after buying 2.61 million shares, have now control over 2.40% of the stake in the company. It holds 14204.0 shares of worth $84.15 million.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) started trading at $25.12, below -$0.2 from concluding price of the previous day. However, the stock later moved at a day high price of 25.25, or with a loss of -3.48%. Stock saw a price change of -11.86% in past 5 days and over the past one month there was a price change of -27.41%. Year-to-date (YTD), ARWR shares are showing a performance of -39.74% which decreased to -39.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.75 but also hit the highest price of $51.11 during that period. The average intraday trading volume for Arrowhead Pharmaceuticals Inc. shares is 1.10 million. The stock is currently trading -20.70% below its 20-day simple moving average (SMA20), while that difference is down -26.24% for SMA50 and it goes to -30.86% lower than SMA200.
BlackRock Fund Advisors acquired 11.54 million shares of Arrowhead Pharmaceuticals Inc. having value of about $372.87 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 0.42 million shares in the company valued at close to $10275749.12, or have control over 3.78% stake in the company. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) currently have 106.04M outstanding shares and institutions hold larger chunk of about 68.10% of that. Holding of mutual funds in the company is about 4.74% while other institutional holders and individual stake holders have control over 41.65% and 26.45% of the stake respectively.
The stock has a current market capitalization of $2.79B and its 3Y-monthly beta is at 1.08. It has posted earnings per share of -$1.47 in the same period. It has Quick Ratio of 4.70 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ARWR, volatility over the week remained 6.37% while standing at 4.50% over the month.
Analysts are in expectations that Arrowhead Pharmaceuticals Inc. (ARWR) stock would likely to be making an EPS of -$0.63 in the current quarter, while forecast for next quarter EPS is -$0.69 and it is -$2.82 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.09 which is $0.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.41 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -23.00% while it is estimated to decrease by -34.40% in next year. EPS is likely to grow at an annualized rate of 7.33% for next 5-years, compared to annual growth of -29.10% made by the stock over the past 5-years.
Analysts at 12 brokerage firms have issued recommendations for the Arrowhead Pharmaceuticals Inc. (ARWR)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 12 Wall Street analysts, 9 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on September 09, 2022 offering an Equal-weight rating for the stock and assigned a target price of $41 to it. Coverage by Robert W. Baird stated Arrowhead Pharmaceuticals Inc. (ARWR) stock as an Outperform in their note to investors on May 11, 2022, suggesting a price target of $60 for the stock. On January 19, 2022, Goldman Resumed their recommendations, while on August 06, 2021, Chardan Capital Markets Reiterated their ratings for the stock with a price target of $94. Stock get a Neutral rating from Robert W. Baird on June 04, 2021.
Leave a Reply